Screener
Bausch + Lomb BLCO Pharmaceuticals — Acquisitions (Note 5)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.
The source filing: Bausch + Lomb’s 10-Q, filed April 30, 2025.
- Filed
- Apr 30, 2025
- Fiscal quarter
- Q1 FY2025
- Calendar quarter
- Q1 2025
- Accession
- 0001860742-25-000008
| (in millions) | Vision Care | Pharmaceuticals | Surgical | Total |
|---|---|---|---|---|
| Balance, January 1, 2024 | $3,556 | $693 | $326 | $4,575 |
| Acquisitions (Note 5) | — | — | 29 | 29 |
| Foreign exchange | (27) | (49) | (5) | (81) |
| Balance, December 31, 2024 | 3,529 | 644 | 350 | 4,523 |
| Acquisitions (Note 5) | — | — | — | — |
| Foreign exchange | 6 | 33 | 5 | 44 |
| Balance, March 31, 2025 | $3,535 | $677 | $355 | $4,567 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch + Lomb's pharmaceuticals — acquisitions (note 5)?
- Bausch + Lomb (BLCO) reported pharmaceuticals — acquisitions (note 5) of $0 in Q1 2025.
- What does pharmaceuticals — acquisitions (note 5) mean?
- Measures the cash outflows or consideration transferred for the purchase of external businesses, product lines, or intellectual property specifically integrated into the pharmaceutical segment. This metric highlights the company's inorganic growth strategy and its commitment to expanding its ophthalmic drug portfolio.
Ask your AI about Bausch + Lomb's pharmaceuticals — acquisitions (note 5).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude